Feb 9, 2022
Pfizer Biontech Decline in market as ‘omicron’ retreats
Shares of vaccine makers slumped again, losing over $20 billion in market value Immediately after Pfizer Inc. issued revenue guidance of its C-19 jab and pill that fell short of analyst expectations. BioNTechRead More